Abstract
Anemia is a very common complication of chronic kidney disease (CKD). Anemia confers significant risk of cardiovascular disease and contributes to decreased quality of life. Anemia in CKD patients can be multi-factorial, including but not invariably due to the underlying renal insufficiency. Identifying the type of anemia is important in this group of patients and can often be challenging. Diagnosing anemia of renal disease due to erythropoietin (EPO) deficiency is a diagnosis of exclusion. Erythropoiesis stimulating agents (ESA) are the mainstay for the treatment of anemia secondary to CKD. However, over the last four years the use of ESA in the treatment of anemia in CKD patients has undergone a severe interrogation as several trials have reported adverse outcomes with targeting higher hemoglobin (Hb) levels with these agents. Thereby, this review describes the pathophysiology of anemia in CKD patients, diagnosis and the current role of ESA’s as it relates to anemia of CKD as well as safety and efficacy of ESA’s.
Keywords: Anemia, Chronic Kidney Disease, ESA, Iron.
Reviews on Recent Clinical Trials
Title:Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials
Volume: 7 Issue: 3
Author(s): Vinayak Ramanath, Diptesh Gupta, Juhi Jain, Kunal Chaudhary and Ravi Nistala
Affiliation:
Keywords: Anemia, Chronic Kidney Disease, ESA, Iron.
Abstract: Anemia is a very common complication of chronic kidney disease (CKD). Anemia confers significant risk of cardiovascular disease and contributes to decreased quality of life. Anemia in CKD patients can be multi-factorial, including but not invariably due to the underlying renal insufficiency. Identifying the type of anemia is important in this group of patients and can often be challenging. Diagnosing anemia of renal disease due to erythropoietin (EPO) deficiency is a diagnosis of exclusion. Erythropoiesis stimulating agents (ESA) are the mainstay for the treatment of anemia secondary to CKD. However, over the last four years the use of ESA in the treatment of anemia in CKD patients has undergone a severe interrogation as several trials have reported adverse outcomes with targeting higher hemoglobin (Hb) levels with these agents. Thereby, this review describes the pathophysiology of anemia in CKD patients, diagnosis and the current role of ESA’s as it relates to anemia of CKD as well as safety and efficacy of ESA’s.
Export Options
About this article
Cite this article as:
Ramanath Vinayak, Gupta Diptesh, Jain Juhi, Chaudhary Kunal and Nistala Ravi, Anemia and Chronic Kidney Disease: Making Sense of the Recent Trials, Reviews on Recent Clinical Trials 2012; 7 (3) . https://dx.doi.org/10.2174/157488712802281222
DOI https://dx.doi.org/10.2174/157488712802281222 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Twin-to-Twin Transfusion Syndrome: From Placental Anastomoses to Long-Term Neurodevelopmental Outcome
Current Pediatric Reviews Bisphenol A as a Factor in the Mosaic of Autoimmunity
Endocrine, Metabolic & Immune Disorders - Drug Targets Augmentation of Creatine in the Heart
Mini-Reviews in Medicinal Chemistry CYP-Mediated Clozapine Interactions: How Predictable Are They?
Current Drug Metabolism Fabry Disease and Cardiovascular Involvement
Current Pharmaceutical Design Regulative Roles of Ghrelin in Ingestive Behavior, Upper Gastrointestinal Motility, and Secretion
Current Nutrition & Food Science Myocardial Energy Transport and Heart Failure
Current Cardiology Reviews Catheter Ablation of Lone Atrial Fibrillation
Current Pharmaceutical Design Therapeutic Effects of Renal Denervation on Renal Failure
Current Neurovascular Research Skeletal Myoblasts for Heart Regeneration and Repair: State of the Art and Perspectives on the Mechanisms for Functional Cardiac Benefits
Current Pharmaceutical Design Voltammetric Stripping Methods for Direct Determination of Disopyramide
Current Pharmaceutical Analysis Meet Our Editorial Board Member:
Current Vascular Pharmacology Management of Inflammation by Natural Polyphenols: A Comprehensive Mechanistic Update
Current Medicinal Chemistry Natural Polyphenols and Cardioprotection
Mini-Reviews in Medicinal Chemistry The Impact of Uncontrolled Hypertension on the Longitudinal Systolic Function of the Left Ventricle
Current Hypertension Reviews Interferon Treatment in Patients with Hypereosinophilia
Current Drug Targets Development of Aldose Reductase Inhibitors for the Treatment of Inflammatory Disorders and Cancer: Current Drug Design Strategies and Future Directions
Current Medicinal Chemistry Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology Novel approaches to examine the regulation of voltage-gated calcium channels in the heart
Current Molecular Pharmacology A Review on the Sex Differences in Organ and System Pathology with Alcohol Drinking
Current Drug Abuse Reviews